Publications



Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients


Lewis, R., Habringer, S., Kircher, M., Hefter, M., Peuker, C. A., Werner, R., Ademaj-Kospiri, V., Gable, A., Weber, W., Wester, H. J., Buck, A., Herhaus, P., Lapa, C. & Keller, U. (2021). Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res, 11, 77.

DOI:10.1186/s13550-021-00822-6

Spinal Manifestation of Malignant Primary (PLB) and Secondary Bone Lymphoma (SLB)


Barz, M., Aftahy, K., Janssen, I., Ryang, Y.M., Prokop, G., Combs, S.E., Jost, P.J., Meyer, B., Gempt, J. (2021). Curr Oncol 28, 3891-3899.

DOI:10.3390/curroncol28050332

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies


Odinius, T.O., Buschhorn, L., Wagner, C., Hauch, R.T., Dill, V., Dechant, M., Buck, M.C., Shoumariyeh, K., Moog, P., Schwaab, J., Reiter, A., Brockow, K., Gotze, K., Bassermann, F., Hockendorf, U., Branca, C., Jost, P.J., Jilg, S. (2021). J Cancer Res Clin Oncol.

DOI:10.1007/s00432-021-03827-9

Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification


Konukiewitz, B., Schmitt, M., Silva, M., Pohl, J., Lang, C., Steiger, K., Halfter, K., Engel, J., Schlitter, A.M., Boxberg, M., Pfarr, N., Wilhelm, D., Foersch, S., Tschurtschenthaler, M., Weichert, W., Jesinghaus, M. (2021). Br J Cancer.

DOI:10.1038/s41416-021-01553-0

CD64-expressing phagocyte subset mediates protection against toxic kidney injury and failure


Salei, N., Ji, X., Pakalniskyte, D., Kuentzel, V., Rambichler, S., Li, N., Moser, M., Steiger, K., Buch, T., Anders, H.J., Schraml, B.U. (2021). Proc Natl Acad Sci U S A 118.

DOI:10.1073/pnas.2022311118

In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets


Carlet, M., Volse, K., Vergalli, J., Becker, M., Herold, T., Arner, A., Senft, D., Jurinovic, V., Liu, W.H., Gao, Y., Dill, V., Fehse, B., Baldus, C.D., Bastian, L., Lenk, L., Schewe, D.M., Bagnoli, J.W., Vick, B., Schmid, J.P., Wilhelm, A., Marschalek, R., Jost, P.J., Miething, C., Riecken, K., Schmidt-Supprian, M., Binder, V., Jeremias, I. (2021). Nat Commun 12, 5655.

DOI:10.1038/s41467-021-25963-z

Regulation of T Cell Responses by Ionic Salt Signals


Zielinski, C.E. (2021). Cells 10.

DOI:10.3390/cells10092365

Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma


Heider, M., Grass, S., Dill, V., Ramisch, S., Winter, C., Verbeek, M., Gotze, K.S., Bassermann, F., Jilg, S. (2021). Transfus Apher Sci 60, 103197.

DOI:10.1016/j.transci.2021.103197

Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis


Reich, M., Spomer, L., Klindt, C., Fuchs, K., Stindt, J., Deutschmann, K., Hohne, J., Liaskou, E., Hov, J.R., Karlsen, T.H., Beuers, U., Verheij, J., Ferreira-Gonzalez, S., Hirschfield, G., Forbes, S.J., Schramm, C., Esposito, I., Nierhoff, D., Fickert, P., Fuchs, C.D., Trauner, M., Garcia-Beccaria, M., Gabernet, G., Nahnsen, S., Mallm, J.P., Vogel, M., Schoonjans, K., Lautwein, T., Kohrer, K., Haussinger, D., Luedde, T., Heikenwalder, M., Keitel, V. (2021). J Hepatol 75, 634-646.

DOI:10.1016/j.jhep.2021.03.029

Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities


Chu, C.F., Sabath, F., Fibi-Smetana, S., Sun, S., Ollinger, R., Noessner, E., Chao, Y.Y., Rinke, L., Winheim, E., Rad, R., Krug, A.B., Taher, L., Zielinski, C.E. (2021). Frontiers in Immunology 12.

DOI:10.3389/fimmu.2021.601080